Poliomyelitis gained significant public attention in developed countries, leading to substantial efforts for vaccine development, culminating in Jonas Salk's successful inactivated polio vaccine in 1953. Field trials in 1954 demonstrated its effectiveness in reducing paralytic cases, prompting a redefinition of the disease and improved diagnostic criteria. Consequently, the incidence of paralytic poliomyelitis significantly declined following the vaccine's introduction.